Huiwen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huiwen Wang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Guangju Ji
Institute of Biomedical Research, Henan Academy of Sciences, China
4 shared publications Xinlong Qiao
Yuan Sheng Biotechnology Ltd. Qingdao China
3 shared publicationsJun Wang
Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publicationsKeqi Zhu
Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publicationsQun Liu
Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publicationsShaole Song
Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Advanced Science
- p. e77808
Neuron‐Derived Vesicular circMagi1 Restrains Vascular Repair After Ischemic Stroke by Promoting TRIM65‐Mediated ANXA2 Degradation
Circular RNAs (circRNAs) contribute to stroke pathogenesis, yet their intercellular functions within the ischemic neurovascular unit remain poorly defined. Profiling of plasma extracellular vesicles (EVs) revealed a higher abundance of circMagi1 in patients with acute ischemic stroke compared with healthy controls. This upregulation was recapitulated in the ischemic mouse brain, where cell‐type‐resolved analyses identified injured neurons as a primary source of circMagi1‐containing EVs that accumulate in endothelial cells. Mechanistically, endothelial circMagi1 binds ANXA2 and enhances its engagement with TRIM65, thereby promoting TRIM65‐mediated ANXA2 ubiquitination and proteasomal degradation and restraining angiogenesis. To therapeutically target this axis in vivo, treatment with siCircMagi1‐RVG‐EVs was initiated on post‐stroke day 1 and maintained thereafter, while siTrim65‐Ang2‐EVs were introduced from either day 1 or day 9. Among the schedules tested, adding siTrim65‐Ang2‐EVs from day 9 was associated with greater neurovascular recovery than sustained circMagi1‐targeted treatment alone or co‐initiation on day 1. Together, these findings delineate a vesicle‐mediated signaling axis linking neuronal injury to impaired vascular repair and support further evaluation of delayed TRIM65 inhibition during sustained circMagi1 suppression.
- 15 October 2026
- Published by Wiley in Advanced Science
- p. e77808
Open AccessNeuron‐Derived Vesicular circMagi1 Restrains Vascular Repair After Ischemic Stroke by Promoting TRIM65‐Mediated ANXA2 Degradation
Circular RNAs (circRNAs) contribute to stroke pathogenesis, yet their intercellular functions within the ischemic neurovascular unit remain poorly defined. Profiling of plasma extracellular vesicles (EVs) revealed a higher abundance of circMagi1 in patients with acute ischemic stroke compared with healthy controls. This upregulation was recapitulated in the ischemic mouse brain, where cell‐type‐resolved analyses identified injured neurons as a primary source of circMagi1‐containing EVs that accumulate in endothelial cells. Mechanistically, endothelial circMagi1 binds ANXA2 and enhances its engagement with TRIM65, thereby promoting TRIM65‐mediated ANXA2 ubiquitination and proteasomal degradation and restraining angiogenesis. To therapeutically target this axis in vivo, treatment with siCircMagi1‐RVG‐EVs was initiated on post‐stroke day 1 and maintained thereafter, while siTrim65‐Ang2‐EVs were introduced from either day 1 or day 9. Among the schedules tested, adding siTrim65‐Ang2‐EVs from day 9 was associated with greater neurovascular recovery than sustained circMagi1‐targeted treatment alone or co‐initiation on day 1. Together, these findings delineate a vesicle‐mediated signaling axis linking neuronal injury to impaired vascular repair and support further evaluation of delayed TRIM65 inhibition during sustained circMagi1 suppression.
- Open Access
- 4 September 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-18
Exosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease characterized by pulmonary fibrosis and lung dysfunction, ultimately leading to respiratory failure. Many preclinical studies have investigated the therapeutic potential of stem cell-derived exosomes in this disease, particularly mesenchymal stem cell-derived exosomes. However, the effects of embryonic stem cell-derived exosomes in IPF remain unclear. Methods: We established a bleomycin (BLM)-induced pulmonary fibrosis mice model and administered human embryonic stem cell exosomes (hESC-exo) from the first day after BLM treatment. The effects of hESC-exo were assessed by pulmonary function tests, biochemical analysis, histochemistry, quantitative real-time polymerase chain reaction (qPCR), and western blot (WB). RNA-seq was used to screen for the potential therapeutic targets of hESC-exo in fibrotic lungs; the identified signaling axis was characterized using a luciferase assay, qPCR, and WB. Results: Results indicated hESC-exo administration notably alleviated inflammation, removed deposited collagen, and rescued alveolar architecture in the lungs of BLM-induced mice. In vivo and in vitro tests revealed that hESC-exo-derived miR-17-5p directly bound thrombospondin-2 (Thbs2) to regulate inflammation and fibrosis; thus, hESC-exo protected against BLM toxicity in the lungs via the miR-17-5p/Thbs2 axis. Conclusion: These results suggest a promising new treatment for fibrosis-associated diseases.
- 4 September 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-18
Open AccessExosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease characterized by pulmonary fibrosis and lung dysfunction, ultimately leading to respiratory failure. Many preclinical studies have investigated the therapeutic potential of stem cell-derived exosomes in this disease, particularly mesenchymal stem cell-derived exosomes. However, the effects of embryonic stem cell-derived exosomes in IPF remain unclear. Methods: We established a bleomycin (BLM)-induced pulmonary fibrosis mice model and administered human embryonic stem cell exosomes (hESC-exo) from the first day after BLM treatment. The effects of hESC-exo were assessed by pulmonary function tests, biochemical analysis, histochemistry, quantitative real-time polymerase chain reaction (qPCR), and western blot (WB). RNA-seq was used to screen for the potential therapeutic targets of hESC-exo in fibrotic lungs; the identified signaling axis was characterized using a luciferase assay, qPCR, and WB. Results: Results indicated hESC-exo administration notably alleviated inflammation, removed deposited collagen, and rescued alveolar architecture in the lungs of BLM-induced mice. In vivo and in vitro tests revealed that hESC-exo-derived miR-17-5p directly bound thrombospondin-2 (Thbs2) to regulate inflammation and fibrosis; thus, hESC-exo protected against BLM toxicity in the lungs via the miR-17-5p/Thbs2 axis. Conclusion: These results suggest a promising new treatment for fibrosis-associated diseases.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1353: ELEVATED HEPATIC GDP-FUCOSE TRANSPORTER SLC35C1 ATTENUATES CHOLESTATIC LIVER INJURY
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1353: ELEVATED HEPATIC GDP-FUCOSE TRANSPORTER SLC35C1 ATTENUATES CHOLESTATIC LIVER INJURY
- Open Access
- 8 February 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (2) , 1-8
CUGBP1, a crucial factor for heart regeneration in mice
The mammalian heart is capable of achieving perfect regeneration following cardiac injury through sustained cardiomyocyte proliferation during the early period after birth. However, this regenerative capacity is lost by postnatal day 7 and throughout adulthood. CUGBP1 is critical for normal cardiac development but its role in heart regeneration remains unclear. Cardiac CUGBP1 levels are high in the early postnatal period and soon downregulate to adult levels within 1 week following birth in mice. The simultaneously diminished regenerative capacity and CUGBP1 levels by postnatal day lead us to hypothesize that CUGBP1 may be beneficial in heart regeneration. In this study, the function of CUGBP1 in heart regeneration was tested by a heart apex resection mouse model. We demonstrate that cardiac inactivation of CUGBP1 impairs neonatal heart regeneration at P1, in turn, replenishment of CUGBP1 levels prolong regenerative potential at P8 and P14. Furthermore, our results imply that the Wnt/β-catenin signaling and GATA4 involve in the CUGBP1 modulated neonatal heart regeneration. Altogether, our findings support CUGBP1 as a key factor promoting post-injury heart regeneration and provide a potential therapeutic method for heart disease.
- 8 February 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (2) , 1-8
Open AccessCUGBP1, a crucial factor for heart regeneration in mice
The mammalian heart is capable of achieving perfect regeneration following cardiac injury through sustained cardiomyocyte proliferation during the early period after birth. However, this regenerative capacity is lost by postnatal day 7 and throughout adulthood. CUGBP1 is critical for normal cardiac development but its role in heart regeneration remains unclear. Cardiac CUGBP1 levels are high in the early postnatal period and soon downregulate to adult levels within 1 week following birth in mice. The simultaneously diminished regenerative capacity and CUGBP1 levels by postnatal day lead us to hypothesize that CUGBP1 may be beneficial in heart regeneration. In this study, the function of CUGBP1 in heart regeneration was tested by a heart apex resection mouse model. We demonstrate that cardiac inactivation of CUGBP1 impairs neonatal heart regeneration at P1, in turn, replenishment of CUGBP1 levels prolong regenerative potential at P8 and P14. Furthermore, our results imply that the Wnt/β-catenin signaling and GATA4 involve in the CUGBP1 modulated neonatal heart regeneration. Altogether, our findings support CUGBP1 as a key factor promoting post-injury heart regeneration and provide a potential therapeutic method for heart disease.
- 1 February 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Vol. 1862 (2) , 209-218
A positive feedback regulation of Heme oxygenase 1 by CELF1 in cardiac myoblast cells
- 1 February 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Vol. 1862 (2) , 209-218
A positive feedback regulation of Heme oxygenase 1 by CELF1 in cardiac myoblast cells
- Open Access
- 5 March 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (5) , 815-820
15-deoxy-Δ12,14-prostaglandin J2 ameliorates endotoxin-induced acute lung injury in rats
Background: A proinflammatory milieu emerging in the lung due to neutrophil accumulation and activation is a key in the pathogenesis of acute lung injury (ALI). 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), one of the terminal products of the cyclooxygenase-2 pathway, is known to be the endogenous ligand of peroxisome proliferator-activated receptor γ (PPAR-γ) with multiple physiological properties. Growing evidence indicates that 15d-PGJ2 has anti-inflammatory, anti-proliferative, cytoprotective and pro-resolving effects. We investigated whether 15d-PGJ2 has a protective effect against endotoxin-induced acute lung injury in rats. Methods: Twenty-four male Wistar rats were randomly assigned into four groups (n=6 per group): sham+vehicle group, sham+15d-PGJ2 group, LPS+vehicle group, and LPS+15d-PGJ2 group. The rats were given either lipopolysaccharide (LPS, 6 mg/kg intravenously) or saline, and pretreated with 15d-PGJ2 (0.3 mg/kg intravenously) or its vehicle (dimethyl sulphoxide) 30 minutes before LPS. Histological alterations, wet/dry weight (W/D) ratio and myeloperoxidase (MPO) activity as well as tumor necrosis factor (TNF)-α and cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels were determined in lung tissues four hours after LPS injection. Immunohistochemical analysis for intercellular adhesion molecule-1 (ICAM-1) expression and Western blotting analysis for nuclear factor (NF)-κB p65 translocation and IκBα protein levels were also studied. Results: 15d-PGJ2 pretreatment significantly attenuated LPS-induced lung injury, and reduced the increased W/D ratio, MPO activity, TNF-α, CINC-1 levels, and ICAM-1 expression in the lung. 15d-PGJ2 also suppressed the nuclear NF-κB p65 translocation and increased cytosolic IκBα levels. Conclusions: 15d-PGJ2 protects against endotoxin-induced acute lung injury, most likely through the reduction of pro-inflammatory protein levels during endotoxemia subsequent to the inhibition of NF-κB activation.
- 5 March 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (5) , 815-820
Open Access15-deoxy-Δ12,14-prostaglandin J2 ameliorates endotoxin-induced acute lung injury in rats
Background: A proinflammatory milieu emerging in the lung due to neutrophil accumulation and activation is a key in the pathogenesis of acute lung injury (ALI). 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), one of the terminal products of the cyclooxygenase-2 pathway, is known to be the endogenous ligand of peroxisome proliferator-activated receptor γ (PPAR-γ) with multiple physiological properties. Growing evidence indicates that 15d-PGJ2 has anti-inflammatory, anti-proliferative, cytoprotective and pro-resolving effects. We investigated whether 15d-PGJ2 has a protective effect against endotoxin-induced acute lung injury in rats. Methods: Twenty-four male Wistar rats were randomly assigned into four groups (n=6 per group): sham+vehicle group, sham+15d-PGJ2 group, LPS+vehicle group, and LPS+15d-PGJ2 group. The rats were given either lipopolysaccharide (LPS, 6 mg/kg intravenously) or saline, and pretreated with 15d-PGJ2 (0.3 mg/kg intravenously) or its vehicle (dimethyl sulphoxide) 30 minutes before LPS. Histological alterations, wet/dry weight (W/D) ratio and myeloperoxidase (MPO) activity as well as tumor necrosis factor (TNF)-α and cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels were determined in lung tissues four hours after LPS injection. Immunohistochemical analysis for intercellular adhesion molecule-1 (ICAM-1) expression and Western blotting analysis for nuclear factor (NF)-κB p65 translocation and IκBα protein levels were also studied. Results: 15d-PGJ2 pretreatment significantly attenuated LPS-induced lung injury, and reduced the increased W/D ratio, MPO activity, TNF-α, CINC-1 levels, and ICAM-1 expression in the lung. 15d-PGJ2 also suppressed the nuclear NF-κB p65 translocation and increased cytosolic IκBα levels. Conclusions: 15d-PGJ2 protects against endotoxin-induced acute lung injury, most likely through the reduction of pro-inflammatory protein levels during endotoxemia subsequent to the inhibition of NF-κB activation.